{
    "clinical_study": {
        "@rank": "144685", 
        "arm_group": [
            {
                "arm_group_label": "1A - Dose Escalation Group", 
                "arm_group_type": "Experimental", 
                "description": "Dose escalation: Afatinib and Dasatinib. This study is divided into two parts. The first 8 - 18 people will be entered in the first part, called Phase 1A. Then this part will end."
            }, 
            {
                "arm_group_label": "1B - Extension Group", 
                "arm_group_type": "Experimental", 
                "description": "Extension: Afatinib and Dasatinib. The next 20 people will enter into the second part, called Phase 1B."
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to:\n\n        -  Find out if the study drugs Afatinib and Dasatinib can be safely given together to\n           patients with lung cancer\n\n        -  Learn how these two drugs work in cancer cells when they are combined\n\n        -  Learn more about the side effects of these two drugs when combined\n\n        -  Find the highest doses of the study drugs Afatinib and Dasatinib that can be given\n           safely without causing serious side effects"
        }, 
        "brief_title": "Phase I Trial of Afatinib (BIBW 2992) and Dasatinib in Non-small Cell Lung Cancer (NSCLC)", 
        "completion_date": {
            "#text": "December 2015", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Lung Cancer", 
            "Non-small Cell Lung Cancer (NSCLC)"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Carcinoma, Non-Small-Cell Lung", 
                "Lung Neoplasms"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Pathologically or cytologically documented Stage IIIB/IV non-small cell lung cancer,\n             or unresectable recurrent disease following locoregional treatment.\n\n          -  For Phase 1B Extension Only:\n\n               -  Either or both of the following: A tumor which harbors an activating Epidermal\n                  Growth Factor Receptor (EGFR) - mutation; History of objective response, or\n                  stable disease for at least 6 months, after treatment with erlotinib, afatinib,\n                  or gefitinib.\n\n               -  Either or both of the following: Progression or recurrence of disease after\n                  receiving prior continuous gefitinib, afatinib, or erlotinib; A tumor known to\n                  harbor a de novo T790M mutation, which is known to confer EGFR TKI resistance.\n\n               -  Participants are allowed to have received systemic chemotherapy or\n                  investigational therapy in the intervening period prior to trial enrollment\n\n          -  Capable of giving written informed consent.\n\n          -  Evaluable disease, as follows: For Phase 1A Dose Escalation: Have the presence of any\n             evaluable disease, including bone metastases, effusion, or cystic metastases. For\n             Phase 1B Extension Only: Have progressive and measurable disease as defined by the\n             Response Evaluation Criteria in Solid Tumors (RECIST v 1.1).\n\n          -  Have adequate bone marrow reserve and organ function as follows:\n\n               -  Hematologic: Neutrophil count >1.5 x 10^9/L and platelets > 100 x 10^9/L\n\n               -  Hepatic: total bilirubin \u2264 1.5 times upper limit of normal (ULN); alanine\n                  transaminase (ALT) and aspartate transaminase (AST) \u2264 2.5 times ULN (or \u2264 5\n                  times ULN in case of known liver involvement).\n\n               -  Renal: Serum Creatinine \u2264 1.5 times upper limit of normal (ULN);\n\n          -  Reproductive potential must be either terminated (by surgery, radiation, or\n             menopause) or attenuated by the use of an approved contraceptive method during and\n             for 3 to 6 months following the study.\n\n          -  Participant agrees that IV bisphosphonates will be withheld during the first 8 weeks\n             of dasatinib therapy due to risk of hypocalcemia.\n\n          -  Have recovered from prior drug-related toxicity to Grade \u2264 1 Common Terminology\n             Criteria for Adverse Events (CTCAE) v4, within 21 days of initiation of on-study\n             treatment.\n\n          -  Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 at initial\n             enrollment, as assessed by clinician or investigator.\n\n        Exclusion Criteria:\n\n          -  Have previously completed or withdrawn from this study or any other study\n             investigating dasatinib. Prior treatment with other tyrosine kinases, including\n             afatinib, is acceptable.\n\n          -  Prior recent systemic or investigational therapy within 21 days of initiation of\n             study treatment. An exception is that epidermal growth factor receptor (EGFR)\n             inhibitor may be continued up until 14 days of initiation of study treatment.\n\n          -  Women who are pregnant or breastfeeding. Women must have a negative pregnancy test\n             (\u03b2-HCG test in urine or serum) prior to commencing study treatment.\n\n          -  Patients with documented central nervous system or leptomeningeal metastasis (brain\n             metastasis) at the time of study entry. Patients with prior brain metastasis may be\n             considered if they have completed their treatment for brain metastasis and no longer\n             require corticosteroids.\n\n          -  Patients with disease progression in the central nervous system (CNS) only.\n\n          -  Serious concomitant disorder, including active bacterial, fungal, or viral infection,\n             incompatible with the study (at the discretion of the principal investigator).\n\n          -  Uncorrected severe electrolyte disorder, including severe potassium <3.0 mEq/L) or\n             magnesium ( < 1.0 mEq/L) deficiency.\n\n          -  Any gastrointestinal disorder with diarrhea as a major symptom, such as Crohn's, or\n             pre-existing chronic diarrhea Common Toxicity Criteria (CTC) Grade \u2265 2 of any\n             etiology. Included are malabsorption disorders that in the opinion of the study\n             physician may affect absorption of either afatinib or dasatinib.\n\n          -  Prior major surgery or radiation therapy within 14 days of initiation of treatment.\n\n          -  Electrocardiogram (ECG) abnormalities indicative of arrhythmia (at the discretion of\n             the investigator).\n\n          -  History or presence of clinically relevant cardiovascular abnormalities such as\n             uncontrolled hypertension, congestive heart failure New York Heart Association (NYHA)\n             classification of 3, unstable angina or poorly controlled arrhythmia. Myocardial\n             infarction within 6 months prior to enrollment.\n\n          -  Baseline (< 1 month before treatment) cardiac left ventricular function with resting\n             ejection fraction of less than 50% measured by multigated blood pool imaging of the\n             heart (MUGA scan) or echocardiogram.\n\n          -  Any history of clinically significant ventricular arrhythmias (such as ventricular\n             tachycardia, ventricular fibrillation, congenital long QT syndrome, or Torsades de\n             pointes).\n\n          -  Prolonged QTc interval on pre-entry electrocardiogram (> 470 msec for men and >480\n             msec for women per American College of Cardiology/American Heart Association\n             [AHA/ACC] 2011 scientific statement).\n\n          -  History of significant bleeding disorder unrelated to cancer, including diagnosed\n             congenital bleeding disorders (e.g., von Willebrand's disease).\n\n          -  Patients currently taking drugs that are generally accepted to have a high risk of\n             causing Torsades de Pointes.\n\n          -  Patients with pre-existing interstitial lung disease (ILD), or pericardial / pleural\n             effusion of grade 2 or higher.\n\n          -  Patients who require chronic oxygen therapy for chronic obstructive pulmonary disease\n             or pleural effusions (malignant or benign).\n\n          -  Patients requiring comedication with potent P-gp inhibitors.\n\n          -  Known active hepatitis B infection, known active hepatitis C infection, or known HIV\n             carrier.\n\n          -  Known or suspected active drug or alcohol abuse.\n\n          -  Known hypersensitivity to afatinib, dasatinib, or the excipients of any of the trial\n             drugs."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "38", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "November 26, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01999985", 
            "org_study_id": "MCC-17176", 
            "secondary_id": [
                "BI 1200.166", 
                "BMS CA180-379"
            ]
        }, 
        "intervention": [
            {
                "arm_group_label": "1A - Dose Escalation Group", 
                "description": "1A: Begins Day 8.  Level 1 - 100 mg, Level 2 - 100 mg, Level 3 - 140 mg.", 
                "intervention_name": "Dasatinib - 1A", 
                "intervention_type": "Drug", 
                "other_name": [
                    "SPRYCEL\u00ae", 
                    "BMS-354825", 
                    "tyrosine kinase inhibitor", 
                    "SRC Kinase Inhibitor"
                ]
            }, 
            {
                "arm_group_label": "1A - Dose Escalation Group", 
                "description": "1A: Begins Day 1.  Level 1 - 30 mg, Level 2 - 40 mg, Level 3 - 40 mg.", 
                "intervention_name": "Afatinib - 1A", 
                "intervention_type": "Drug", 
                "other_name": [
                    "BIBW 2992", 
                    "EGFR Inhibitor"
                ]
            }, 
            {
                "arm_group_label": "1B - Extension Group", 
                "description": "In Phase 1B, a mutationally selected 20 participants (total) will be treated at the recommended dose to confirm tolerability and evaluate for early response signal.", 
                "intervention_name": "Dasatinib - 1B", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "1B - Extension Group", 
                "description": "In Phase 1B, a mutationally selected 20 participants (total) will be treated at the recommended dose to confirm tolerability and evaluate for early response signal.", 
                "intervention_name": "Afatinib - 1B", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Mitogens", 
                "Dasatinib"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "keyword": [
            "Epidermal Growth Factor Receptor (EGFR)", 
            "Tyrosine kinase inhibitors", 
            "Neoplasms", 
            "Lung Diseases", 
            "Respiratory Tract Diseases", 
            "Pleural Diseases", 
            "Pleural Neoplasms", 
            "Lung Neoplasms", 
            "Pleural Effusion", 
            "Pleural Effusion, Malignant", 
            "Respiratory Tract Neoplasms", 
            "Thoracic Neoplasms", 
            "Neoplasms by Site", 
            "EGFR mutation", 
            "Afatinib", 
            "Dasatinib", 
            "Carcinoma, Bronchogenic", 
            "Gene Mutation", 
            "T790M mutation.", 
            "Non-small cell lung cancer"
        ], 
        "lastchanged_date": "May 6, 2014", 
        "link": {
            "description": "Moffitt Cancer Center Clinical Trials website", 
            "url": "http://www.moffitt.org/research--clinical-trials/clinical-trials"
        }, 
        "location": {
            "contact": {
                "email": "amanda.carpenter@moffitt.org", 
                "last_name": "Amanda Carpenter", 
                "phone": "813-745-3905"
            }, 
            "facility": {
                "address": {
                    "city": "Tampa", 
                    "country": "United States", 
                    "state": "Florida", 
                    "zip": "33612"
                }, 
                "name": "H. Lee Moffitt Cancer Center and Research Institute"
            }, 
            "investigator": [
                {
                    "last_name": "Ben Creelan, M.D.", 
                    "role": "Principal Investigator"
                }, 
                {
                    "last_name": "Scott Antonia, M.D., Ph.D.", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Alberto Chiappori, M.D.", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Jhanelle Gray, M.D.", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Eric Haura, M.D.", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Mary Pinder, M.D.", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Tawee Tanvetyanon, M.D.", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Charles Williams, M.D.", 
                    "role": "Sub-Investigator"
                }
            ], 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "Phase I Trial Evaluating Safety and Tolerability of the Irreversible Epidermal Growth Factor Receptor Inhibitor Afatinib (BIBW 2992) in Combination With the SRC Kinase Inhibitor Dasatinib for Patients With Non-small Cell Lung Cancer (NSCLC)", 
        "overall_official": {
            "affiliation": "H. Lee Moffitt Cancer Center and Research Institute", 
            "last_name": "Ben Creelan, M.D.", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "December 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "1A - The MTD for this combined treatment will be defined as either:\nThe highest dosage cohort in which six patients had been treated and there were less than two dose limiting toxicities (DLTs) or,\nAfatinib at the highest tolerated dose investigated (40 mg by mouth [PO] daily) plus dasatinib at the highest tolerated dose investigated (cohort 3, 140 mg PO daily).", 
            "measure": "Maximum Tolerated Dose (MTD) of BIBW 2992 in Combination with Dasatinib", 
            "safety_issue": "Yes", 
            "time_frame": "Up to 6 Months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01999985"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Estimate the objective response rate (complete response [CR] and partial response [PR]), and clinical benefit rate, in participants with acquired EGFR resistance. Response Criteria for Phase 1B will follow RECIST v.1.1: Complete Response (CR is defined as disappearance of all target lesions; Partial Response (PR) is defined as at least a 30% decrease in the sum of longest diameter (LD) of target lesions taking as reference the baseline sum LD.", 
                "measure": "Objective Response Rate", 
                "safety_issue": "No", 
                "time_frame": "Up to 6 Months"
            }, 
            {
                "description": "Estimate the 6-month progression free survival (PFS) rate in participants with acquired EGFR resistance. Response Criteria for Phase 1B will follow RECIST v.1.1: Progressive Disease (PD) is defined as at least a 20% increase in the sum of LD of target lesions taking as references the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions.", 
                "measure": "Progression Free Survival Rate", 
                "safety_issue": "No", 
                "time_frame": "Up to 6 Months"
            }
        ], 
        "source": "H. Lee Moffitt Cancer Center and Research Institute", 
        "sponsors": {
            "collaborator": [
                {
                    "agency": "Boehringer Ingelheim", 
                    "agency_class": "Industry"
                }, 
                {
                    "agency": "Bristol-Myers Squibb", 
                    "agency_class": "Industry"
                }
            ], 
            "lead_sponsor": {
                "agency": "H. Lee Moffitt Cancer Center and Research Institute", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "December 2013", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}